FocalTherics: A Pure-Play Pivot into High-Growth Focal Therapy
EDAP transforms into FocalTherics, posts 39% HIFU growth, raises $40M to fund multi-indication expansion.
EDAP · Earnings Call · 2026-08-13
Transformative Rebranding and Strategic Refocus
The second quarter of 2026 marks a watershed moment for EDAP TMS S.A., now rebranded as FocalTherics. CEO Ryan Rhodes opened the call by framing this as "a transformative moment in the evolution of our company's history," highlighting the transition to a pure-play high-growth focal therapy company (“We view this as a transformative moment... including the transition of our name from EDAP to FocalTherics” — Ryan Rhodes, Chief Executive Officer · 2026-08-13). The strategic pivot is underscored by the reclassification of noncore ESWL and distribution businesses into discontinued operations, a move CFO Ken Mobeck explained as removing "a layer of complexity that has made it difficult for investors to understand HIFU's underlying financial trajectory" (“We recognize change introduces a new set of comparisons... we intend to be as clear and consistent as possible” — Ken Mobeck, Chief Financial Officer · 2026-08-13). The company also completed a $40M equity raise (expected to close August 14), fortifying a balance sheet that had been strained by recurring losses and warrant-related charges. This capital infusion is earmarked for three buckets, as Rhodes detailed: accelerated commercial growth, expanded indications (BPH and endometriosis), and new technologies including histotripsy. The capital system sales momentum is already visible—Q2 saw 13 Focal One sales, a 44% year-over-year increase, contributing to HIFU revenue growth of 39% to $13.2M. With an installed base of 184 systems and a qualified pipeline of 300 deals, the commercial engine is clearly firing.Growth Acceleration and Multi-Indication Expansion
The core HIFU business is scaling rapidly. U.S. procedure volumes surged 47% year-over-year, a testament to both deeper penetration in existing accounts and new program launches. Rhodes noted that "we now have 15 U.S. hospital networks that have invested in 2 or more Focal One systems," with notable repeat orders from Cleveland Clinic (now 6 systems globally) and Kaiser Permanente. This is not just a domestic story—international markets contributed 5 capital sales, including Imperial College London converting from a competitive HIFU device to Focal One. The procedure volume growth is a durable recurring revenue driver, as Rhodes emphasized: "the lion's share of revenue will still come from the capital system sales side as of now, but we're encouraged because that was one of the investments we're making to do more on the same platform" (“Yes. So again, the way I would look at it is... we will see notable increases in revenue coming from both capital and from our disposables business” — Ryan Rhodes, Chief Executive Officer · 2026-08-13). Beyond prostate cancer, the new indication strategy is advancing. The BPH program has enrolled 14 patients in Latin America, with U.S. treatments planned later this year. Endometriosis has seen its first commercial program at Toulouse University Hospital, with 11 centers in the training pathway. Management conservatively estimates a TAM of 4.3 million procedures and $10B in potential revenue across all indications. The FDA submission for FocalConnect, a remote connectivity technology, could accelerate training and broaden access—a move that aligns with the global theme of "commercial readiness" seen in this quarter's broader market markers. The financial trajectory is encouraging. Gross margin expanded to 55.6% from 51.1% a year ago, driven by better pricing, cost reductions, and factory absorption. Management reiterated full-year 2026 guidance of $50-54M in core HIFU revenue, implying continued robust growth. As Rhodes noted on the CMS front, "the proposed rule came out from CMS, and it's calling for an 11.6% increase in reimbursement" (“Notably, the proposed rule came out from CMS... we're methodical and very structured in how we offer pricing” — Ryan Rhodes, Chief Executive Officer · 2026-08-13)—the fifth consecutive annual increase, which supports the investment rationale for hospitals. Investor attention will likely focus on the HIFUSA study readout, expected late this year or early next, which Rhodes said "will likely be favorable to the story" (“Yes. Great question, Alex. The HIFUSA study... we know that it will likely be favorable to the story” — Ryan Rhodes, Chief Executive Officer · 2026-08-13). Meanwhile, the company's shares have recovered 17% over the last 90 days, but remain 65% below the 2023 peak—a testament to the market's cautious embrace of this ongoing transformation. In prior quarters, management had already telegraphed the shift toward procedure-led growth. On the Q1 2026 call, Ryan Rhodes noted, "We had good procedure growth and again, on a quarter-over-quarter basis, double-digit growth" (“Yes, Michael. So first off, yes, we had good procedure growth... we're seeing increased demand for non-radical treatments” — Ryan Rhodes, Chief Executive Officer · 2026-05-07). The current quarter's 47% U.S. procedure acceleration marks a clear step-change, validating the strategy of building a recurring revenue base. FocalTherics is no longer a story of restructuring but of execution. With a clean capital structure, a focused product line, and multiple indication drivers, the company is positioned to redefine the standard of care in focal therapy. As Rhodes concluded: "We are excited about the momentum building" (). The next quarters will be critical to see if this momentum translates into sustained profitability and shareholder value.So our pipeline remains extremely strong. As we shown at in the Investor Day event in New York, we have 300 additional deals that we're working through that are qualified